Hypertension
Conditions
Brief summary
The primary objective of this study was to assess whether there is an increased risk of sepsis with the use of telmisartan compared with other ARBs and with the other major antihypertensive classes, including ACEIs, beta-blockers, CCBs and thiazide diuretics. A secondary objective was to assess whether the use of ARBs and ACEIs, compared with the other three major antihypertensive classes and with untreated hypertension, is associated with an increased risk of sepsis. A third objective was to evaluate whether the use of telmisartan compared with other ARBs, ACEIs and other major antihypertensive classes is associated with an increased risk of worse outcomes due to sepsis, in particular acute kidney injury and death
Interventions
DRUGTelmisartan
DRUGOther angiotensin-receptor blockers (ARBs)
DRUGAngiotensin-converting enzyme inhibitors (ACEIs)
DRUGOther major antihypertensive medication classes
e.g. beta-blockers, calcium channel blockers (CCBs), diuretics
Sponsors
Boehringer Ingelheim
Study design
Observational model
CASE_CONTROL
Time perspective
RETROSPECTIVE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
\- Patients, 18 years or older, with at least two-year follow-up in United Kingdom's general practice research database (GPRD), who had a diagnosis of or treatment for hypertension
Exclusion criteria
\- Sepsis, chronic renal failure or on dialysis in the two-year period prior to cohort entry
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Occurence of sepsis, including severe sepsis | Up to 9 years and 5 months | Severe sepsis defined as cases that develop renal failure or die within 30 days |
Outcome results
None listed